

PATIENT INFORMATION (PLEASE PRINT IN BLACK INK)

Last Name First MI
Address Birth Date (MM/DD/YYYY) Sex M F
City SS # International Patient? Yes No
State Zip Home Phone
Hospital/Physician Office Patient ID # Accession #

MEDICAL NECESSITY NOTICE: When ordering tests for which Medicare reimbursement will be sought, physicians (or other individuals authorized by law to order tests) should only order tests that are medically necessary for the diagnosis or treatment of a patient, rather than for screening purposes.

INSURANCE BILLING INFORMATION (PLEASE ATTACH CARD OR PRINT IN BLACK INK)

BILL TO: Client/Institution Medicare Insurance (Complete insurance information below) Patient
PATIENT STATUS: Inpatient Outpatient Non-Hospital Patient Hospital discharge date: MM/DD/YYYY
PRIMARY: Medicare Medicaid (Ohio only) Other Ins. Self Spouse Child

Subscriber Last Name First MI
Beneficiary / Member # Group #
Claims Address City State Zip
SECONDARY: No Yes (if Yes, please attach) ABN: No Yes

DIAGNOSIS CODE (REQUIRED) ICD-10 Codes 1. 2. 3.

ADDITIONAL CLINICAL INFORMATION

Blank lines for additional clinical information.

CLIENT INFORMATION

ORDERING PHYSICIAN CONTACT

Choose one: Clinician Pathologist

Physician Name
NPI #
Physician Phone
Physician Email
Fax report to:
Fax additional report to:

SPECIMEN INFORMATION

Please submit copy of Surgical Pathology report with requisitions

Collection Date (MM/DD/YYYY):
Time: AM PM
Body Site: Client Case #:
Specimen ID:
Paraffin Cell Blocks: Paraffin Tissue Blocks:
Slides, unbaked & unstained
Fixation Type: Formalin Alcohol Other:
Breast Samples: CAP/ASCO Requirements
10% neutral buffered formalin: Yes No Unknown
Fixation time >6 and <72 hours: Yes No Unknown
Cold ischemic time <= 1 hour: Yes No Unknown

AVAILABLE MOLECULAR AND BIOMARKER TESTING WITH INTERPRETATION:

Next-generation sequencing (NGS) panels: CC-SIGN* NTR K 1,2,3 by NGS, CC-SIGN* Targeted Oncology Panel (TOP) by NGS, CC-SIGN* Solid Tumor Gene Fusion NGS Panel (59 gene panel) - refer to SRCNGS gene list on Test Directory.
Other: BRAF V600E by ddPCR BRAFO, KIT D816V by ddPCR K8160, EGFR Hotspot by PCR EGFRID, KRAS Hotspot by PCR KRASID, IDH1 and IDH2 Hotspot by PCR.
Breast: CC-SIGN* TOP NGS Panel includes ESR1/ER, ERBB2/HER2, AKT1, PIK3CA, CCND1, ETV6::NTRK3, MAG3::AKT3, FGFR2::AFF3 + pan cancer markers.
Breast Markers Profile: ER, PR, HER2 by IHC (reflex to FISH if equivocal).
Immunohistochemistry (select any/all): ER, PR, Androgen Receptor, Ki67, HER2 (reflex to in situ hybridization if equivocal), HER2 by FISH (reflex to IHC if Group 2, 3, or 4), Mismatch repair (MMR) by IHC (reflex to MLH1 promoter methylation), PD-L1 by IHC (Clone 22C3).
Colorectal/Small Bowel: CC-SIGN* TOP NGS Panel includes BRAF, KRAS, NRAS, PIK3CA, ERBB2/HER2 + pan cancer markers.
Metastatic Colorectal/Small Bowel Profile: Mismatch repair (MMR) by IHC (reflex to MLH1 promoter methylation), CC-SIGN TOP NGS Panel.
Mismatch repair (MMR) by IHC (reflex to MLH1 promoter methylation), HER2 by IHC (reflex to FISH in equivocal cases), MLH1 promoter methylation (PCR) MLH1PH.
Endometrial/GYN: CC-SIGN* TOP NGS Panel includes ERBB2/HER2, PIK3CA, AKT1, CTNNB1, TP53, NTRK fusions + pan cancer markers.
Mismatch repair (MMR) by IHC (reflex to MLH1 promoter methylation), ER by IHC, PR by IHC, HER2 by IHC (reflex to in situ hybridization if equivocal), Endometrial/GYN (CONTINUED) PD-L1 by IHC (Clone 22C3) - for cervical primary only, POLE Mutation Detection by PCR POLEDD, MLH1 promoter methylation (PCR) MLH1PH.
Gastrointestinal Stromal Tumor: CC-SIGN* TOP NGS Panel includes BRAF, KIT, PDGFRA + pan cancer markers.
Genitourinary: CC-SIGN* TOP NGS Panel includes AR, TP53, TMPRSS2::ERG, TMPRSS2::ETV1, TMPRSS2::ETV4, TMPRSS2::ETV5, SLC45A3::ERG, SLC45A3::BRAF, FGFR3::TACC3 + pan cancer markers.
Mismatch repair (MMR) by IHC (reflex to MLH1 promoter methylation), PD-L1 by IHC for pembrolizumab/Keytruda use (Clone 22C3), TFE3 & TFE6 (FISH) TFEFSH.
Head & Neck and Thyroid: CC-SIGN* TOP NGS Panel includes BRAF, RAS genes, TP53, pTERT, MET, PIK3CA, RET/ALK/BRAF fusions, PAX8::PPARG + pan cancer markers.
CC-SIGN* Head & Neck Gene Fusion NGS Panel, HPV High and Low Risk by in situ hybridization, HPV High Risk by in situ hybridization, HPV Low Risk by in situ hybridization, PD-L1 by IHC (Clone 22C3).
Lung: CC-SIGN* TOP NGS Panel includes BRAF, EGFR, ERBB2/HER2, KRAS, MET, DDR2, MET exon 14 skipping, ALK/RET/ROS1 fusions + pan cancer markers.
Lung Carcinoma (non-squamous NSCLC) Profile: ALK D5F3 by IHC (reflex to FISH), PD-L1 by IHC (Clone 22C3), ROS1 by FISH, RET by FISH, CC-SIGN TOP NGS Panel.
ALK (FISH) FSHLNG, RET (FISH) RET, ROS (FISH) ROS1.
ALK D5F3 by IHC (reflex to FISH), PD-L1 by IHC (Clone 22C3), MGMT Methylation (PCR) MGMT.
Melanoma: CC-SIGN* TOP NGS Panel includes BRAF, KIT, NRAS, pTERT + pan cancer markers.
BRAF V600E by IHC, Cutaneous Melanoma (FISH) CMFISH, PD-L1 by IHC (Clone 22C3).
Neuro: CC-SIGN* TOP NGS Panel includes IDH1/2, H3-3A/B, EGFR, PDGFRA, PIK3CA, EGFR VIII, KIAA1549::BRAF, FGFR1/2/3 mutations and fusions + pan cancer markers.
Glioma panel (1p/19q/EGFR) (FISH), 1p/19q (FISH) IP19Q, EGFR (FISH) EGFRF, MGMT Methylation (PCR) MGMT.
Pancreaticobiliary: CC-SIGN* TOP NGS Panel includes KRAS, TP53, BRAF, GNAS, NRAS, pTERT, ERBB2/HER2, PIK3CA, FGFR1/2/3, EGFR, NTRK fusions + pan cancer markers.
Soft Tissue/Sarcoma: CC-SIGN* TOP NGS Panel includes MYC amplification, KIT, BRAF, PDGFRA, GNAS, GNAQ, GNA11, H3-3A/B, CTNNB1 + pan cancer markers.
CC-SIGN* Solid Tumor Gene Fusion NGS Panel (59 gene panel) - refer to SRCNGS gene list on Test Directory.
FISH (select any/all): DDIT3 (CHOP)/GLI1 (12q13) DDIT3, EWSR1 (22q12) EWSR, FOXO1A (13q14) FKHR, FUS (16p11) FUS, MDM2 amplification MDM2, MYC amplification (angiosarcoma) MYCAMP, SS18 (18q11) STY.
Stomach/EGJ: CC-SIGN* TOP NGS Panel includes TP53, ERBB2/HER2 amplification, NTRK fusions + pan cancer markers.
Stomach/EGJ Profile: Mismatch repair (MMR) by IHC, HER2 by IHC (reflex to FISH in equivocal cases), PD-L1 by IHC (Clone 22C3).
Mismatch repair (MMR) by IHC (reflex to MLH1 promoter methylation), HER2 by IHC (reflex to FISH in equivocal cases), PD-L1 by IHC (Clone 22C3), Claudin 18 by IHC.
Other Testing: C4d by IHC, HPV High and Low Risk by in situ hybridization, HPV High Risk only by in situ hybridization, HPV Low Risk only by in situ hybridization, MSI by PCR Analysis MSIID, Mismatch repair (MMR) by IHC (reflex to MLH1 promoter methylation), MLH1 promoter methylation (PCR) MLH1PH, HER2 by IHC for enherdu treatment.
Oncology FISH: REFER TO ONCOLOGY FISH PROBE LIST. Indicate probe(s):

FISH Panels

PANEL NAME	Probes included		Accepted Specimen Sources			
	QTY	Target Locations	Blood	Bone Marrow	FFPET	Cell Block*
Aggressive B-Cell Lymphoma	4	BCL2, BCL6, MYC, IGH::MYC	x	x	x	
Acute Myeloid Leukemia	4	PML::RARA, RUNX1::RUNX1T1, CBFβ::MYH11, MLL	x	x		
B Lymphoblastic Leukemia	6	BCR::ABL, CRLF2, CRLF2::IGH, ETV6::RUNX1, MLL, Trisomy 4/10	x	x		
CLL	3	CLL1, CLL2, IGH::CCND1	x			
Cutaneous Melanoma	5	RREB1, CCND1, MYB, MYC, CDKN2A			x	
Glioma	3	1p36, 19q13, EGFR			x	
Myelodysplastic Syndrome	3	5q, 7q, 20q, CEP 8	x	x		
Myeloproliferative Neoplasms	4	BCR::ABL, PDGFRA, PDGFRB, FGFR1	x	x		
Plasma Cell Myeloma	5**	RBI/TP53, CKS1B/CDKN2C, CEP 9/CEP 15, IGH, IGH::CCND1 **Reflex to IGH::MMSET and IGH::MAF if indicated.*		x		
TFEFSH	2	TFE3, TFEB			x	
UroVysion	4	CEP 3, CEP 7, CEP 17, 9p21	Thin prep slide			

*Must be formalin fixed. Alcohol fixed cell blocks will be rejected.

FISH Single Target

PROBE NAME	Chromosomal / Target Location	Blood	Bone Marrow	FFPET	Cell Block*	Thin Prep Slide
1p	1p36			x		
5q	5p15/5q31	x	x			
7q	CEP7/7q31	x	x			
19q	19q13			x		
20q	20q12 <i>Only offered with CEP 8</i>	x	x			
ALK for NSCLC	2p23			x	x	x
BCL2	18q21	x	x	x		
BCL6	3q27	x	x	x		
BCRABL	t(9;22)(q34;q11.2)	x	x			
BIRC3::MALT	t(11;18)(q22;q21)			x		
CBFB::MYH11	16q22-Inversion 16	x	x			
CDKN2A	9p21 <i>Only offered as part of Cutaneous Melanoma & UroVysion Panels</i>			x		x
CCND1	11q13	x	x	x		
CEP 3	Centromere of chromosome 3 <i>Only offered as part of UroVysion Panel</i>					x
CEP 4	Centromere of chromosome 4 <i>Only offered with CEP 10</i>	x	x			
CEP 7	Centromere of chromosome 7 <i>Only offered as part of UroVysion Panel</i>					x
CEP 8	Centromere of chromosome 8 <i>Only offered with 20q</i>	x	x			
CEP 9	Centromere of chromosome 9 <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
CEP 10	Centromere of chromosome 10 <i>Only offered with CEP 4</i>	x	x			
CEP 15	Centromere of chromosome 15 <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
CEP 17	Centromere of chromosome 17 <i>Only offered as part of UroVysion Panel</i>					x

PROBE NAME	Chromosomal / Target Location	Blood	Bone Marrow	FFPET	Cell Block*	Thin Prep Slide
CEP X	Centromere of X chromosome <i>Only offered with CEP Y (DXY3)</i>	x				
CEP Y (DXY3)	Centromere of Y chromosome <i>Only offered with CEP X</i>	x				
CEP Y (DZY1)	Yqh of Y Chromosome	x				
CHOP/DDIT3	12q13			x		
CKS1B/CDKN2C	1p31.1q21 <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
CLL1	17p13.11q22 <i>Only offered as part of CLL Panel</i>	x	x			
CLL2	D13S319/CEP 12/13q24 <i>Only offered as part of CLL Panel</i>	x	x			
EGFR	7p11.2			x		
ETV6::RUNX1	t(12;21)(p13;q22)	x	x			
EWSR1	22q12			x		
FGFR1	8p12	x	x			
FOXO1	13q14			x		
FUS	16p11.2			x		
HER2	17q12			x		
IGH	14q23	x	x	x		
IGH::BCL2	t(14;18)(q32;q21)	x	x	x		
IGH::CCND1	t(11;14)(q13;q32)	x	x	x		
IGH::MAF	t(14;16)(q32;q23) <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
IGH::MMSET	t(4;14)(p16q32) <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
IGH::MYC	t(8;14)(q24;q32)	x	x	x		
MALT1	18q21			x		
MDM2	12q15			x		
MLL	11q23	x	x			
MYB	6q23 <i>Only offered as part of Cutaneous Melanoma Panel</i>			x		
MYC-Break apart	8q24	x	x	x		
MYC-Amplification	8q24			x		
PDGFRA	4q12	x	x			
PDGFRB	5q32	x	x			
PML::RARA	t(15;17)(q22;q21)	x	x			
RARA	17q21	x	x			
RBI/TP53	13q17p <i>Only offered as part of Plasma Cell Myeloma Panel</i>		x			
RET	10q11.21			x	x	
ROS1	6q22			x	x	
RREB1	6p25 <i>Only offered as part of Cutaneous Melanoma Panel</i>			x		
RUNX1::RUNX1T1	t(8;21)(q21;q22)	x	x			
SRY	Yp11.3	x				
SS18::SYT	t(X;18)(p11;q11)			x		
TFE3	Xp11.23			x		
TFEB	6p21.2			x		
XIST	Xq13.2	x				

*Must be formalin fixed. Alcohol fixed cell blocks will be rejected.